Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    Fragrances to treat allergies? Microba and IFF enter stage two of novel treatments
    • News

  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership
    RAS Technology dives deeper into European wagering with Playbook Engineering partnership
    • News

  • BluGlass signs $2.6 million contract with North Carolina State Uni to develop lasers
    BluGlass signs $2.6 million contract with North Carolina State Uni to develop lasers
    • News

  • Markets continue to push higher as Powell signals peak rates
    Markets continue to push higher as Powell signals peak rates
    • Market Update

  • Amid debt dispute, Electro Optic Systems reports revenue guidance of $210 to $230 million
    Amid debt dispute, Electro Optic Systems reports revenue guidance of $210 to $230 million
    • News

  • Use your mobile to check for arrhythmia as Advanced Health Intelligence launches AF-Scan
    Use your mobile to check for arrhythmia as Advanced Health Intelligence launches AF-Scan
    • News

  • The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday
    The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday
    • News

  • US markets see late drive higher, XJO to open flat
    US markets see late drive higher, XJO to open flat
    • Market Update

  • Little Green Pharma has big news: a new CEO and 37% revenue growth
    Little Green Pharma has big news: a new CEO and 37% revenue growth
    • News

  • The BESS-T bet: GenusPlus and Samsung joint venture awarded $200m to build energy solution
    The BESS-T bet: GenusPlus and Samsung joint venture awarded $200m to build energy solution
    • News

MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms

  • In News
  • June 15, 2020
  • Alfred Chan
MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms

Health tech company MyFiziq (ASX: MYQ) has partnered with Canadian firm NuraLogix which will leverage the two company’s patented imaging technology. Using a smartphone camera, transdermal imaging and artificial intelligence (AI), the newly combined tech aims to determine a user’s probability of having COVID-19, as well as their risk of developing diseases that result in 70% of deaths globally. 

The Memorandum of Understanding (MoU) brings together MyFiziq’s existing smartphone screening technology and NuraLogix’s Transdermal Optical Imaging (TOI™) to extract blood flow information from a user’s face after taking a 30-second selfie video. 

Upon use of the non-invasive screening, users are provided with information about blood pressure, stress levels and heart rate amongst other parameters. Using this screening technology which is then processed by AI, the app can then offer an assessment on the user’s cardiovascular disease risk, diabetes risk and stroke risk which combine for 70% of global deaths annually. 

“This is an extremely exciting partnership for the companies. Bringing our technologies together will not only create a one of a kind solution, furthermore it will be unrivalled. Our offerings in a standalone environment have a deep patent suite,” said MyFiziq CEO, Vlado Bosanac. 

“When combining the company solutions, we form not only a unique offering, but one that enhances both companies’ ability to be the dominant player in digital health and convenience. The solutions form an easy to use, comprehensive review of an individual, accurately, privately, and conveniently from their mobile phone.

Beyond screening for the aforementioned disease risks, NuraLogix has been in collaboration with St. Michael’s Hospital, University of Toronto, and Zhongda Hospital in China to test symptom profiles of COVID-19 patients. Being developed into a smartphone app, NuraLogix is confident their imaging AI can determine the likelihood of a user having COVID-19 versus a seasonal flu or cold. 

The app will initially be trialed by The Serfaty Clinic in Brazil and WeSure/WeFit in China before MyFiziq looks to broaden distribution globally. 

Organisations around the world have been exploring the potential combination of thermal imaging cameras with drone technology to scan crowds as a measure in the fight against current and future pandemics.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership - December 4, 2023
  • The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday - December 1, 2023
  • InteliCare forges strategic partnership with Bolton Clarke to digitise aged care with AI technology - November 28, 2023
  •  
  •  
  •  
  •  
  • ai
  • artificial intelligence
  • asx myq
  • coronavirus screening
  • health tech
  • medtech
  • MyFiziq
  • MYQ
  • Nuralogix
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership - December 4, 2023
  • The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday - December 1, 2023
  • InteliCare forges strategic partnership with Bolton Clarke to digitise aged care with AI technology - November 28, 2023

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is an Analyst at Emerald Financial, specialising in ASX-listed small cap companies.
Latest posts by Alfred Chan (see all)
  • RAS Technology dives deeper into European wagering with Playbook Engineering partnership - December 4, 2023
  • The Calmer Co reports monthly record of eCommerce kava sales thanks to Black Friday - December 1, 2023
  • InteliCare forges strategic partnership with Bolton Clarke to digitise aged care with AI technology - November 28, 2023
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.